Market Cap 23.16B
Revenue (ttm) 3.25B
Net Income (ttm) -1.29B
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -39.59%
Debt to Equity Ratio 0.02
Volume 7,241,366
Avg Vol 940,940
Day's Range N/A - N/A
Shares Out 252.88M
Stochastic %K 67%
Beta 1.27
Analysts Strong Sell
Price Target $123.94

Company Profile

BioNTech SE, together with its subsidiaries, engages in the development and commercialization of immunotherapies in Germany. The company offers BNT162, an mRNA vaccine for the treatment of SARS-CoV-2 virus. It also develops oncology drugs under Phase III clinical trial, including Gotistobart for metastatic non-small cell lung cancer, Pumitamig for small cell lung cancer and advanced/metastatic triple-negative breast cancer, and Trastuzumab pamirtecan for metastatic breast cancer and epirubicin a...

Industry: Biotechnology
Sector: Healthcare
Phone: 49 6131 9084
Fax: 49 6131 9084
Address:
An der Goldgrube 12, Mainz, Germany
StocktwitsNews
StocktwitsNews Aug. 19 at 5:49 PM
TEM, BNTX, MRVI, RGEN, NVAX Stock Rallies As Moderna-Merck Cancer Vaccine Clears Late-stage Trial $TEM $NVAX $BNTX $MRVI $RGEN https://stocktwits.com/news/equity/markets/tem-bntx-mrvi-rgen-nvax-stock-rallies-as-moderna-merck-cancer-vaccine-clears-late-stage-trial/cZYdob1RJlk
0 · Reply
lecorb
lecorb Aug. 19 at 4:43 PM
$MSTX $MRNA $GDXU $TEM $BNTX 👏👏👏
0 · Reply
Vete
Vete Aug. 19 at 4:23 PM
0 · Reply
notreload_ai
notreload_ai Aug. 19 at 3:51 PM
$MRNA Phase 3 melanoma success boosts cancer vaccines. $SLS GPS data is imminent, Maxim keeps Buy/$30 PT. $BNTX also in focus. https://notreload.xyz/xy/moderna-cancer-vaccine-win-why-sellas-sls-is-next/
1 · Reply
outlawinvestor1
outlawinvestor1 Aug. 19 at 3:38 PM
$NVAX $BNTX congrats to $MRNA shareholders! 🎉 great science wins every time!
0 · Reply
mastix
mastix Aug. 19 at 3:08 PM
$BNTX Is looking better everyday....
0 · Reply
DocPharm
DocPharm Aug. 19 at 2:45 PM
0 · Reply
SniperPro
SniperPro Aug. 19 at 2:41 PM
$MRNA $BNTX $LXRX $MRK $NVO WHAT A BEAUTIFUL DAY! ☀️📈 My bio babies are PRINTING GREEN! 💚💸 Straight to the moon, baby 🚀🌙 — we’re catching bids, stacking gains, and watching those candles rip! 🔥📊 Green across the tape. Bulls are COOKING. 🐂💰 LFG!!! 🍾🚀 ....
0 · Reply
Chelsea100
Chelsea100 Aug. 19 at 2:08 PM
$NVAX NVAX is moving higher too — and that makes sense. The Moderna/Merck Phase 3 success validates the cancer-vaccine concept, not just mRNA. Big Pharma will now look even harder at alternative and complementary platforms. That could make protein/antigen-based approaches + powerful immune enhancers like Matrix-M significantly more interesting. Remember: Matrix-M is already being evaluated across multiple oncology targets by partners, including a leading Top-10 pharma/oncology player. MRNA +129%, BNTX +24%, and even NVAX +8% today. The market clearly sees a positive read-through for the broader cancer-vaccine space. Matrix-M Oncology just became a lot more interesting. $MRNA $BNTX $NVAX
0 · Reply
jimmysyw
jimmysyw Aug. 19 at 2:00 PM
$BNTX lets go BNTX!
1 · Reply
Latest News on BNTX
BioNTech rises 20.3%

2026-08-19T16:05:37.000Z - 3 hours ago

BioNTech rises 20.3%


BioNTech rises 21.6%

2026-08-19T14:00:12.000Z - 5 hours ago

BioNTech rises 21.6%


BioNTech price target raised to $142 from $138 at Canaccord

2026-08-05T11:05:37.000Z - 14 days ago

BioNTech price target raised to $142 from $138 at Canaccord


BioNTech price target lowered to $125 from $130 at Citi

2026-08-05T10:35:32.000Z - 14 days ago

BioNTech price target lowered to $125 from $130 at Citi


BioNTech SE Earnings Call Transcript: Q2 2026

Aug 4, 2026, 8:00 AM EDT - 15 days ago

BioNTech SE Earnings Call Transcript: Q2 2026


BioNTech SE Earnings release: Q2 2026

Aug 4, 2026, 8:00 AM EDT - 15 days ago

BioNTech SE Earnings release: Q2 2026


BioNTech SE Slides: Q2 2026

Aug 4, 2026, 8:00 AM EDT - 15 days ago

BioNTech SE Slides: Q2 2026


BioNTech says Sobi's Oelkers will replace Sahin as CEO

Aug 3, 2026, 5:29 AM EDT - 16 days ago

BioNTech says Sobi's Oelkers will replace Sahin as CEO


BioNTech CEO Ugur Sahin to depart, Guido Oelkers to succeed

2026-08-03T09:05:08.000Z - 16 days ago

BioNTech CEO Ugur Sahin to depart, Guido Oelkers to succeed


This Biotech's Cancer Portfolio Could End Its Rough Patch

May 27, 2026, 11:07 AM EDT - 3 months ago

This Biotech's Cancer Portfolio Could End Its Rough Patch


BioNTech SE Transcript: AGM 2026

May 15, 2026, 8:00 AM EDT - 3 months ago

BioNTech SE Transcript: AGM 2026


BioNTech Announces New ADS Repurchase Program

May 7, 2026, 6:45 AM EDT - 3 months ago

BioNTech Announces New ADS Repurchase Program


BioNTech SE Earnings Call Transcript: Q1 2026

May 5, 2026, 8:00 AM EDT - 3 months ago

BioNTech SE Earnings Call Transcript: Q1 2026


BioNTech SE Earnings release: Q1 2026

May 5, 2026, 8:00 AM EDT - 3 months ago

BioNTech SE Earnings release: Q1 2026


BioNTech SE Slides: Q1 2026

May 5, 2026, 8:00 AM EDT - 3 months ago

BioNTech SE Slides: Q1 2026


BioNTech SE Earnings Call Transcript: Q4 2025

Mar 10, 2026, 8:00 AM EDT - 5 months ago

BioNTech SE Earnings Call Transcript: Q4 2025


BioNTech SE Annual report: Q4 2025

Mar 10, 2026, 8:00 AM EDT - 5 months ago

BioNTech SE Annual report: Q4 2025


BioNTech SE Earnings release: Q4 2025

Mar 10, 2026, 8:00 AM EDT - 5 months ago

BioNTech SE Earnings release: Q4 2025


BioNTech SE Slides: Q4 2025

Mar 10, 2026, 8:00 AM EDT - 5 months ago

BioNTech SE Slides: Q4 2025


Scientists behind COVID-19 vaccine will depart BioNTech

Mar 10, 2026, 7:40 AM EDT - 5 months ago

Scientists behind COVID-19 vaccine will depart BioNTech


BioNTech Cofounders to Leave to Form New Company

Mar 10, 2026, 6:50 AM EDT - 5 months ago

BioNTech Cofounders to Leave to Form New Company


BioNTech says collaboration with Pfizer remains unchanged

Nov 13, 2025, 8:17 AM EST - 9 months ago

BioNTech says collaboration with Pfizer remains unchanged

PFE


BioNTech SE Transcript: R&D Day

Nov 11, 2025, 9:00 AM EST - 10 months ago

BioNTech SE Transcript: R&D Day


BioNTech SE Slides: R&D Day

Nov 11, 2025, 9:00 AM EST - 10 months ago

BioNTech SE Slides: R&D Day


BioNTech SE Earnings Call Transcript: Q3 2025

Nov 3, 2025, 8:00 AM EST - 10 months ago

BioNTech SE Earnings Call Transcript: Q3 2025


BioNTech SE Earnings release: Q3 2025

Nov 3, 2025, 8:00 AM EST - 10 months ago

BioNTech SE Earnings release: Q3 2025


BioNTech SE Slides: Q3 2025

Nov 3, 2025, 8:00 AM EST - 10 months ago

BioNTech SE Slides: Q3 2025


BioNTech lifts 2025 revenue guidance on BMS partnership payment

Nov 3, 2025, 6:47 AM EST - 10 months ago

BioNTech lifts 2025 revenue guidance on BMS partnership payment


BioNTech to Host Innovation Series R&D Day on November 11, 2025

Oct 28, 2025, 7:45 AM EDT - 10 months ago

BioNTech to Host Innovation Series R&D Day on November 11, 2025


StocktwitsNews
StocktwitsNews Aug. 19 at 5:49 PM
TEM, BNTX, MRVI, RGEN, NVAX Stock Rallies As Moderna-Merck Cancer Vaccine Clears Late-stage Trial $TEM $NVAX $BNTX $MRVI $RGEN https://stocktwits.com/news/equity/markets/tem-bntx-mrvi-rgen-nvax-stock-rallies-as-moderna-merck-cancer-vaccine-clears-late-stage-trial/cZYdob1RJlk
0 · Reply
lecorb
lecorb Aug. 19 at 4:43 PM
$MSTX $MRNA $GDXU $TEM $BNTX 👏👏👏
0 · Reply
Vete
Vete Aug. 19 at 4:23 PM
0 · Reply
notreload_ai
notreload_ai Aug. 19 at 3:51 PM
$MRNA Phase 3 melanoma success boosts cancer vaccines. $SLS GPS data is imminent, Maxim keeps Buy/$30 PT. $BNTX also in focus. https://notreload.xyz/xy/moderna-cancer-vaccine-win-why-sellas-sls-is-next/
1 · Reply
outlawinvestor1
outlawinvestor1 Aug. 19 at 3:38 PM
$NVAX $BNTX congrats to $MRNA shareholders! 🎉 great science wins every time!
0 · Reply
mastix
mastix Aug. 19 at 3:08 PM
$BNTX Is looking better everyday....
0 · Reply
DocPharm
DocPharm Aug. 19 at 2:45 PM
0 · Reply
SniperPro
SniperPro Aug. 19 at 2:41 PM
$MRNA $BNTX $LXRX $MRK $NVO WHAT A BEAUTIFUL DAY! ☀️📈 My bio babies are PRINTING GREEN! 💚💸 Straight to the moon, baby 🚀🌙 — we’re catching bids, stacking gains, and watching those candles rip! 🔥📊 Green across the tape. Bulls are COOKING. 🐂💰 LFG!!! 🍾🚀 ....
0 · Reply
Chelsea100
Chelsea100 Aug. 19 at 2:08 PM
$NVAX NVAX is moving higher too — and that makes sense. The Moderna/Merck Phase 3 success validates the cancer-vaccine concept, not just mRNA. Big Pharma will now look even harder at alternative and complementary platforms. That could make protein/antigen-based approaches + powerful immune enhancers like Matrix-M significantly more interesting. Remember: Matrix-M is already being evaluated across multiple oncology targets by partners, including a leading Top-10 pharma/oncology player. MRNA +129%, BNTX +24%, and even NVAX +8% today. The market clearly sees a positive read-through for the broader cancer-vaccine space. Matrix-M Oncology just became a lot more interesting. $MRNA $BNTX $NVAX
0 · Reply
jimmysyw
jimmysyw Aug. 19 at 2:00 PM
$BNTX lets go BNTX!
1 · Reply
Stocktwits
Stocktwits Aug. 19 at 1:08 PM
"Hey, Stocktwits AI, what are the best looking setups today?" $MRNA is the story driving the entire board today. Moderna's cancer-vaccine Phase 3 win has the stock up 90%+ and still running, trending #1, which makes it too extended to chase as a fresh long, but it's dragging a real cluster of sympathy names with it. $BNTX is the cleanest of the sympathy plays, up over 15% with a healthy majority-bullish crowd (60.87% bull posts) even though the sentiment reads BEARISH, it's one of those spots where the raw split tells a better story than the headline score. Trending #15. $MRK is arguably the more fundamentally grounded play, since it's the actual co-development partner on the winning trial rather than just a sympathy mover. Up nearly 7%, sentiment NEUTRAL on score but 90.32% bullish posts, trending #4. $TEM is also catching a bid, up over 13%, though message volume is LOW and one poster summed it up well calling it "a little sympathy move off $MRNA," so it's the more speculative, lower-conviction way to play the theme. Trending #8. $MRVL is a separate story worth watching, up over 12% on its own catalyst: a roughly $12 billion custom-chip and warrant deal with Google. It's EXTREMELY_BULLISH (score 76) and trending #2, though sharper posters are flagging that the warrant structure could mean tens of millions of shares of future dilution once Google's cumulative revenue with Marvell crosses a high threshold. Connect your favorite LLM to our MCP for FREE and start doing your own prompting today: ai.stocktwits.com
0 · Reply
BTC321
BTC321 Aug. 19 at 12:51 PM
$NVAX $NVAX Moderna's INTerpath-001 Phase 3 win de-risks the entire concept of immune-based cancer therapy. MRNA rips, $BNTX +15% Here's where Novavax fits — closer than people think: Per CEO John Jacobs on the Q2 call, interest in Matrix-M is at an all-time high, with an active MTA with a top-10 pharma / immuno-oncology leader and encouraging preclinical data. A Matrix-M licensing deal with major biotech could land anytime — a real, near-term catalyst. Different lane: Novavax is protein + Matrix-M, not mRNA. Matrix-M drives cross-presentation and CD8 T-cell responses — exactly what cancer vaccines need. Stanford's Dr. Michael Lin just flagged why the high-valency particle approach boosts affinity maturation. Moderna proved the concept in humans today. Novavax could monetize its adjuvant into that same booming space via licensing anytime. If immune-based cancer vaccines work as a class, there's room for more than one platform — and a non-mRNA, better-tolerated approach could carve a real niche. The concept just got de-risked for everyone. Novavax's Matrix-M licensing catalyst could land anytime. 🚀 Just my personal opinion. Not financial advice. DYOR.
1 · Reply
eightytwentie
eightytwentie Aug. 19 at 12:49 PM
$BNTX moderna has validated the mRNA platform for oncology Of course we already knew this but that event has also validated BioNTech’s pipeline
0 · Reply
eightytwentie
eightytwentie Aug. 19 at 12:47 PM
$BNTX $MRNA @Samishere What say you? What say you now you dumb kunt ?
0 · Reply
healthmaster
healthmaster Aug. 19 at 12:34 PM
$BNTX Here's my take on BNTX You hire a launch-execution CEO when you expect products to hit the market, not when the pipeline is failing. something is definitely cooking.
0 · Reply
minime2022
minime2022 Aug. 19 at 12:26 PM
$BNTX looking jealous at MRNA 🫩
0 · Reply
tkstockpicker
tkstockpicker Aug. 19 at 12:24 PM
$BNTX MRNA pulling up my horse too. Will it stick though…
0 · Reply
Pillemann1
Pillemann1 Aug. 19 at 12:07 PM
$BNTX I am afraid this will not hold. But her potential is….
0 · Reply
AIIAAIIA_88
AIIAAIIA_88 Aug. 19 at 11:59 AM
$MRNA $BNTX LMAO! The conspiracy nut jobs are taking one in you-know-where today! They deserve it too. JMO
0 · Reply
AIIAAIIA_88
AIIAAIIA_88 Aug. 19 at 11:49 AM
0 · Reply
AIIAAIIA_88
AIIAAIIA_88 Aug. 19 at 11:45 AM
$MRNA $BNTX OK! Keep on making your investment decisions based on crazy homeless nut jobs posting moronic conspiracy stories. LOL JMO
0 · Reply
birdflustocks
birdflustocks Aug. 19 at 11:28 AM
$BNTX $MRNA Great news for mRNA cancer immunotherapy from Moderna! BioNTech results are expected next year. "Merck and Moderna Announce Phase 3 INTerpath-001 Trial of Intismeran Autogene Plus KEYTRUDA® Met Endpoints of Recurrence-Free Survival (RFS) and Distant Metastasis-Free Survival (DMFS) in Patients With Completely Resected Stage IIB-IV Melanoma" "BNT113 is an mRNA cancer immunotherapy candidate encoding a fixed set of two oncoproteins that are frequently found in human papillomavirus type 16 positive (“HPV16+”) solid tumors." "BNT116 is an mRNA cancer immunotherapy candidate encoding a fixed set of six non-mutated antigens that were identified to be frequently expressed in non-small cell lung cancer (“NSCLC”)." "Autogene cevumeran (BNT122/RO7198457) is an individualized mRNA cancer immunotherapy candidate encoding patient-specific tumor neoantigens aiming to induce an immune response against the patient’s individual tumor."
0 · Reply